RecruitingMetastatic Colorectal Cancer (CRC)

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

33 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

Sponsor: Summit Therapeutics

You may qualify if…

✓ 1. ECOG performance status score of 0 or 1
✓ 2. Expected life expectancy ≥ 6 months
✓ 3. Patients with histologically or cytologically confirmed metastatic CRC
✓ 4. No prior systemic therapy for metastatic CRC
✓ 5. At least 1 measurable noncerebral lesion

You may not qualify if…

✕ 1. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease
✕ 2. Known BRAF V600E mutant status
✕ 3. Current presence of significant radiographic or clinical manifestations of gastrointestinal (GI) obstruction
✕ 4. Ascites requiring paracentesis within last 30 days
✕ 5. Patients who have received prior immunotherapy or anti-angiogenic therapy for colorectal cancer
✕ 6. Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
✕ 7. Resectable disease